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ABSTRACT
Background Rapid diagnostic tests (RDTs) are widely 
used for diagnosing Plasmodium vivax malaria, especially 
in resource- limited countries. However, the impact of RDTs 
on P. vivax malaria incidence and national medical costs 
has not been evaluated. We assessed the impact of RDT 
implementation on P. vivax malaria incidence and overall 
medical expenditures in South Korea and performed a 
cost–benefit analysis from the payer’s perspective.
Methods We developed a dynamic compartmental model 
for P. vivax malaria transmission in South Korea using 
delay differential equations. Long latency and seasonality 
were incorporated into the model, which was calibrated 
to civilian malaria incidences during 2014–2018. We 
then estimated averted malaria cases and total medical 
costs from two diagnostic scenarios: microscopy only and 
both microscopy and RDTs. Medical costs were extracted 
based on data from a hospital in an at- risk area for P. 
vivax malaria and were validated using Health Insurance 
Review and Assessment Service data. We conducted 
a cost–benefit analysis of RDTs using the incremental 
benefit:cost ratio (IBCR) considering only medical costs and 
performed a probabilistic sensitivity analysis to reflect the 
uncertainties of model parameters, costs and benefits.
Results The results showed that 55.3% of new P. vivax 
malaria cases were averted, and $696 214 in medical 
costs was saved over 10 years after RDT introduction. The 
estimated IBCR was 2.5, indicating that RDT implementation 
was beneficial, compared with microscopy alone. The IBCR 
was sensitive to the diagnosis time reduction, infectious 
period and short latency period, and provided beneficial 
results in a benefit over $10.6 or RDT cost under $39.7.
Conclusions The model simulation suggested that RDTs 
could significantly reduce P. vivax malaria incidence 
and medical costs. Moreover, cost–benefit analysis 
demonstrated that the introduction of RDTs was beneficial 
over microscopy alone. These results support the need for 
widespread adoption of RDTs.
INTRODUCTION
Despite the government’s vigorous efforts, 
Plasmodium vivax malaria has not been erad-
icated in South Korea since its re- emergence 
in 1993 from a soldier in military service near 
the demilitarised zone, as shown in online 
supplemental figure 1.1 The WHO has recom-
mended that South Korea eradicate malaria 
by 2023,2 and the Korea Centers for Disease 
Control and Prevention (KCDC) has launched 
the ‘Five- Year Action Plan for Malaria Eradica-
tion’ (2019–2023), including the introduction 
and insurance coverage for malaria rapid diag-
nostic tests (RDTs).
RDTs were developed in the early 1990s for 
the simple, rapid and accurate diagnosis of 
malaria.3 4 The high accuracy of the RDT has 
been proven in previous studies. According 
to a Cochrane review, the sensitivity and 
Key questions
What is already known?
 ► There are relatively few studies on the modelling of 
Plasmodium vivax malaria, and the seasonality and 
long incubation period of P. vivax malaria are not well 
reflected in available models.
 ► Although rapid diagnostic tests (RDTs) are wide-
ly used for diagnosing P. vivax malaria, the impact 
of RDTs on P. vivax malaria incidence and national 
medical costs has not been evaluated.
What are the new findings?
 ► Using national surveillance data and climate data, 
we developed a dynamic model for P. vivax malaria 
in South Korea, explaining seasonality and long incu-
bation period intuitively.
 ► The introduction of RDT remarkably reduced medical 
costs as well as malaria cases. Besides, the cost–
benefit analysis showed beneficial results.
What do the new findings imply?
 ► The model we developed can be applied for assess-
ing P. vivax malaria transmission in other countries 
and also can be extended to P. falciparum malaria.
 ► The regimens to analyse the impact of RDT imple-
mentation on disease burden and cost provide use-
ful tools to prepare guidelines to achieve the goal of 
malaria eradication in many areas, including South 
Korea.
2 Kim JH, et al. BMJ Global Health 2021;6:e004292. doi:10.1136/bmjgh-2020-004292
BMJ Global Health
specificity of RDT are 99% in endemic countries.5 A 
study conducted in South Korea also showed more than 
99% concordance.6 In addition, according to the WHO 
Malaria Rapid Diagnostic Test Performance report, the 
false- positive rate is 0 in several tests commercialised 
for P. vivax.7 RDTs are widely used in countries with 
poor medical resources, especially where the use of 
light microscopy is limited; therefore, WHO has recom-
mended the implementation of RDTs for diagnosing 
malaria, published relevant guidelines and released 
results of RDT kits annually to ensure quality.7 8
There have been numerous studies on mathematical 
modelling of malaria. However, most studies have focused 
on P. falciparum malaria, with few studies focusing on P. vivax 
malaria. Recently, several studies have been conducted on 
P. vivax malaria in South Korea.9–11 However, these studies 
did not provide a reliable evidence for model calibration. 
Hence, it is crucial to develop an accurate model for P. 
vivax malaria for the assessment of the RDT introduction 
in South Korea.
Although previous studies have reported microscopy- 
based and RDT- based detection of P. vivax malaria, studies 
to verify the effects of RDTs have been conducted mostly 
in resource- limited settings.12–14 Most of the studies which 
have performed cost- effectiveness analyses used decision 
tree models and concluded that RDT use was more cost- 
effective than microscopy or clinical- based diagnosis.15–17 
Some studies concluded that microscopy is cost- effective 
or that RDT is effective but costly; however, they also used 
a decision tree model that could underestimate RDT 
efficiency.18 19 The introduction of RDTs would incur 
additional costs for diagnosis but could save unnecessary 
medical expenses by reducing the diagnostic time in the 
settings where a microscopy- based diagnosis is readily acces-
sible. This introduction could also contribute to reducing 
malaria incidence due to reduced chances for secondary 
malaria infection. Therefore, research on the effects of 
RDT introduction is important not only from medical 
but also from health policy perspectives as it is related to 
medical expenses.
Therefore, we developed a dynamic compartmental 
mathematical model for P. vivax malaria to assess the 
impact of RDT initiation on malaria incidence and overall 
medical expenditures in South Korea, and performed a 
cost–benefit analysis from the payer’s perspective. This is 
the first study to assess the influence of RDTs in a country 
with a highly qualified medical environment and will 
provide evidence for the inclusion of RDTs in national 
health insurance coverage.
METHODS
Study design and data sources
This study considered two diagnostic scenarios. The 
base scenario was to diagnose only with microscopy, and 
the control scenario was to diagnose using both micros-
copy and RDT at the same time. Since microscopy- based 
diagnosis has remained the gold standard after the 
introduction of RDTs in South Korea in 2012, no patient 
was diagnosed with P. vivax malaria using only an RDT. 
We predicted future malaria incidences and total medical 
costs over the next 10 years for both scenarios. We then 
estimated the incremental benefit:cost ratios (IBCRs) of 
the introduction of RDTs.
For model calibration, malaria incidence data in 
malaria- risk areas, including Incheon, Gyeonggi and 
Gangwon provinces, for the last 5 years (2014–2018) were 
obtained from the annual report of KCDC. To reflect 
realistic demographic and climatic conditions in these 
regions, data from the Korean Statistical Information 
Service and the Korea Meteorological Administration 
were obtained and used for model parameter setting.20–22
To estimate the overall medical cost and to perform a 
cost–benefit analysis of RDT use, data from the National 
Health Insurance Ilsan Hospital (NHIIH) and the Health 
Insurance Review and Assessment Service (HIRA) were 
used. The NHIIH is a general hospital with 822 beds 
located in an area at risk for P. vivax malaria. We reviewed 
the medical records of patients diagnosed with P. vivax 
malaria at NHIIH between January 2009 and December 
2018. We also extracted data from the HIRA, which 
is a nationwide, mandatory insurance database for all 
enrolled Korean citizens. All citizens are obliged to be 
enrolled in the National Health Insurance System. Under 
this system, all costs for medical care on National Health 
Insurance or Medical Aid are claimed to the HIRA for 
reimbursement from the National Health Insurance. 
The data from the HIRA have been shown to be reliable, 
and many studies have been conducted in this manner in 
South Korea.23 24
Modelling and interventions
Since malaria is a vector- borne disease, the model was 
stratified into two species, human and mosquito, as 
shown in figure 1. We divided the model into susceptible 
( Sh ), exposed ( Eh ), infectious ( Ih ) and treated ( Th ) states 
for the human population and into aquatic (A ), suscep-
tible ( Sv ), exposed ( Ev ) and infectious ( Iv ) states for the 
mosquito population.
Newborn babies enter the susceptible human ( Sh ) state 
at a rate of  µh  and leave the model if they die at a rate of  δh
 . Once humans are infected by infectious mosquitoes ( Iv ) 
at a rate of  Ih , they move into the exposed state ( Eh ) and 
can have either short ( τs ) or long ( τl ) latency periods. 
This is an essential characteristic of P. vivax malaria and is 
implemented by delay differential equations; the detailed 
equations are in the online supplemental material 1. If 
the disease develops sufficiently for the transmission of 
the parasite to susceptible mosquitoes ( Sv ), they progress 
to the infectious stage ( Iv ). We assumed that all patients 
are diagnosed and treated at a rate of  γh  and move to  Th  
as soon as they start treatment. Since the accuracy of the 
RDT for P. vivax has been proven to be very high, we have 
not considered a false- negative rate. Treated humans ( Th
 ) leave the compartment at a rate of  ρh , and there is a 
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possibility  q  of relapse. Otherwise, the patients return to 
the susceptible group ( Sh ).
Adult mosquitoes ( Nv ) lay eggs at a rate of  µa ; however, 
the size of the immature mosquito population is limited 
to ka because of the capacity of the sites with proper envi-
ronments for breeding and egg development. Immature 
mosquitoes (A ) can either die at a rate of  δa  or grow into 
susceptible adult mosquitoes ( Sv ) at a rate of  µv . By biting 
infectious humans ( Ih ), susceptible mosquitoes can be 
infected at a rate of  Iv  and move into the exposed stage 
( Ev ) and progress into the infectious stage at a rate of  µv
 . Adult mosquitoes at all stages can fail to survive and die 
at a rate of  δv .
The model parameters were categorised into three 
types, namely, those for humans, mosquitoes and trans-
mission parameters induced by the contact between 
humans and mosquitoes. The demographic parameter 
values for humans were obtained from the statistical 
data,20 21 and parameters for the latency periods, infec-
tious period and relapse were based on malaria reports 
from the KCDC1 and previous studies.11 25–29 The treat-
ment start rate, which was estimated as the reciprocal of 
the average infectious period, was set to 1/4 (1/days) 
based on reports of malaria- risk areas.1
As the mosquito life cycle depends on the climate, we 
assumed most of the mosquito- related model parame-
ters depended on temperature and referred to previous 
laboratory- based studies.25 26 Detailed descriptions of 
the model parameters and values are included in online 
supplemental table 1.
We calibrated the model using civilian malaria inci-
dence data in malaria- risk areas (Incheon, Gyeonggi and 
Gangwon provinces) in South Korea from 2014 to 2018 
obtained from the KCDC. The least- squares method was 
used to estimate three uncertain parameters: transmis-
sion probability from  Iv  to  Sh  ( βhv ), transmission proba-
bility from  Ih  to  Sv  ( βvh ) and probability of having a short 
latency period ( p ). The data and model prediction from 
the estimated parameters are displayed in online supple-
mental figure 2.
In South Korea, microscopy- based methods have 
been continuously used as the gold standard method 
for malaria diagnosis. In 2012, RDTs were introduced in 
the NHIIH, which, combined with microscopy, resulted 
in a reduction in the median of 12 hours required for 
diagnosis based on the result reporting time. Therefore, 
in the model, we configured two diagnostic scenarios by 
setting  γh = 1/4  for the microscopy scenario (microscopy 
only) and  γh = 1/3.5  for the microscopy+RDT scenario. 
The sensitivity analysis assumed an infectious period of 
up to 5 days for the microscopy scenario and a reduction 
in diagnostic time of up to 1 day for the microscopy+RDT 
scenario.
Medical costs
We used the microcosting approach to estimate the 
average medical costs per patient for one episode of 
malaria from each data source. We included the cost 
for administering medications, the cost for injection, a 
fee for procedure or surgery, laboratory tests, imaging 
studies including CT and ultrasound, medical devices/
supplies and blood transfusion. The prices of RDT and 
microscopy were extracted based on NHIIH data as well. 
All costs and prices are presented in US dollars based on 
Figure 1 Diagram of the Plasmodium vivax malaria model. The subscripts  h and  v denote the human and vector, respectively. 
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the 2019 yearly average exchange rate of $1165.65. The 
estimated average medical costs per patient were $799.02 
for microscopy only and $796.56 for both microscopy 
and RDT.
In HIRA data, patients diagnosed with P. vivax malaria 
were defined according to the appropriate diagnosis 
code using the Korean Classification of Disease, which 
is based on the International Classification of Diseases, 
10th Revision, Clinical Modification. The diagnosis 
codes for P. vivax malaria were B51 and B54. However, 
it was not possible to clearly distinguish whether P. vivax 
malaria patients were diagnosed by microscopy alone or 
by microscopy and RDTs, as RDT use was not subject to 
reimbursement. Therefore, for 2012, the year of RDT 
introduction, we defined patients diagnosed by micros-
copy alone as patients diagnosed with P. vivax malaria in 
2011 and patients diagnosed by microscopy and RDT as 
patients diagnosed with P. vivax malaria in 2013. The esti-
mated costs for HIRA data are shown in online supple-
mental table 2.
Cost–benefit analysis
We assumed that the introduction of RDT would incur 
more costs only for the diagnosis. Based on the assump-
tion that delays in diagnosis can lead to additional 
medical resource usage and expenditures, we estimated 
the benefit from the difference between two medical 
costs excluding each diagnostic cost. From NHIIH data, 
the costs of microscopy and RDT were estimated at 
$11.72 and $23.91 each, and the benefit per patient diag-
nosed with RDT was estimated at $26.38. While RDTs may 
provide benefits beyond reducing medical expenditures, 
such as saving time and reducing anxiety and productivity 
loss, this study focused on medical costs due to its tangible 
monetary value. We applied the same method to HIRA 
data to estimate the benefit, which was lower than that 
from the NHIIH data, as shown in online supplemental 
table 2. The only difference between the two data was 
the benefit amount. Therefore, we assessed the results of 
HIRA data using a sensitivity analysis as described in the 
online supplemental material 1.
The IBCR is commonly used to compare benefits and 
costs among multiple interventions. As we estimated the 
benefits from the difference in medical costs between 
scenarios, the IBCR was an appropriate measurement for 
cost–benefit analyses. The formula is shown as follows:
IBCR=incremental benefits/incremental costs
Both benefits and costs are discounted at 3% annually. 
We also investigated the sensitivity of the model param-
eters, costs and benefits to the IBCR in 2028. Univariate 
and bivariate sensitivities were explained by a tornado 
diagram and heat map, respectively.
Patient and public involvement
There was no patient or public involvement in the study.
RESULTS
Malaria incidence
To estimate the impact of RDTs alone, we assumed no 
climate changes in the future prediction and a consistent 
malaria incidence for over 10 years in the microscopy 
scenario, as shown in figure 2. After the introduction of 
RDTs in 2019, malaria cases decreased remarkably over 
10 years. In the first year, the incidences following a long 
latency period were identical in both scenarios as these 
patients were infected in the previous year. However, 
due to the reduced chances of secondary infection from 
Figure 2 Prediction of weekly Plasmodium vivax malaria cases (2019–2028) and impact of RDT implementation. Total cases 
are the sum of short, long and relapse cases. RDT, rapid diagnostic test.
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delayed diagnosis, the incidences after a short latency 
period started to decline, averting 12 cases in 2019. This 
impact propagated to the next year through people 
having a long latency period; consequently, it prevented 
42 new incidences in the second year. After 10 years 
of successive RDT intervention, 84.9% of cases will be 
averted in 2028, and cumulatively, 1025 (55.3%) of cases 
will be prevented.
Medical costs
The total medical costs were computed by multiplying the 
cases by the average medical costs per patient. The lower 
costs and reduced number of cases in the RDT scenario 
resulted in large expenditure savings every year. The cost 
gap between the two scenarios increased, with $93 200 in 
medical cost–savings in 2028 and $696 214 accumulated 
over 10 years.
Cost–benefit analysis
Compared with the microscopy scenario, RDT was bene-
ficial from the first year of its introduction, with the 
IBCR exceeding 1, as shown in figure 3. With increasing 
years, the IBCR increased and the incremental bene-
fits were 2.5 times the incremental costs at the end of 
time horizon. Incremental benefits increased each year. 
Meanwhile, the incremental costs increased up to the 
sixth year and started to decrease thereafter because the 
reduced number of P. vivax malaria cases in the RDT 
scenario resulted in slow increases in cumulative costs. 
Consequently, IBCRs can accelerate to 2.5 in 10 years.
Probabilistic sensitivity analysis
Univariate sensitivity
To determine which parameters were most sensitive 
to the IBCR, we perturbed all parameters by the same 
percentages of their values and selected the eight most 
sensitive parameters. Then, with a realistic parameter 
range, we assumed uniform distribution and re- exam-
ined the sensitivity by sampling 1000 values for each 
parameter. As shown in figure 4, a diagnosis time reduc-
tion, infectious period and short latency period were the 
three most sensitive parameters, followed by the other 
five parameters. A large reduction in diagnosis time due 
to RDT use is beneficial and saves costs, with a nega-
tive IBCR. If the infectious period is longer than that at 
present, more outbreaks occur in the baseline scenario, 
and RDTs become a more beneficial choice. Similarly, a 
shorter short latency period leads to larger outbreaks in 
the base scenario, making RDT introduction more bene-
ficial. Especially for the benefit in the RDT scenario and 
price of RDTs, we estimated the minimum and maximum 
values reaching the threshold of 1. A benefit under $10.6 
or RDT cost over $39.7 cannot achieve beneficial results. 
Changes in the discount rate did not significantly affect 
the results.
Multivariate sensitivity
Among the eight most sensitive parameters in the univar-
iate sensitivity analysis, we selected two combinations for 
bivariate sensitivity analysis. We first chose the infectious 
period versus diagnosis time reduction, as both param-
eters were acting on the same model parameter  γh  in 
different scenarios. As in the univariate sensitivity anal-
ysis, diagnosis time reduction had a greater influence on 
IBCRs than the infectious period, as shown in figure 5A. 
All tested ranges provided beneficial results and cost–
savings for regions with negative IBCR values.
Another combination was the benefit in the RDT 
scenario versus diagnosis time reduction. The more the 
time saved in diagnosis, the greater the benefit of RDT. 
There could be a positive correlation between the two 
parameters. The results in figure 5B show that the intro-
duction of RDTs is a beneficial choice over continuing 
Figure 3 Yearly cumulative incremental benefits and costs, as well as IBCRs, 2019 −2028. IBCR, incremental benefit:cost 
ratio; USD, US dollar
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the use of microscopy alone and also reflects situations 
in which diagnostic time and medical costs may vary by 
region and hospital.
The combined effects of the uncertainty across all 
the eight parameters were further investigated and are 
shown in online supplemental figure 4. We generated 
1000 sets of the eight parameter values drawn from each 
distribution and obtained 1000 sets of incremental costs 
and incremental benefits. The slope of one dot from the 
origin represents one IBCR. Of all IBCRs, 95.5% were 
greater than 1 or negative, which means that the RDT 
introduction is beneficial.
DISCUSSION
We developed a model for P. vivax malaria and investi-
gated how the implementation of RDTs will affect P. vivax 
malaria incidence and medical expenses over the next 
decade. The results verified that RDT introduction was 
not only effective in suppressing new P. vivax malaria 
cases but also had excellent benefits and a significant 
contribution to reducing overall medical expenses.
The key characteristics of P. vivax malaria transmis-
sion are a long latency period and seasonality. These 
two factors are closely related, and their combined 
Figure 4 Box plot of IBCRs in 2028. For each parameter, 1000 samples were drawn from a uniform distribution with a feasible 
parameter range. Dotted line indicates IBCR=1. IBCR, incremental benefit:cost ratio; RDT, rapid diagnostic test.
Figure 5 Heatmap of IBCRs in 2028. (A) Diagnosis time reduction versus infectious period and (B) diagnosis time reduction 
versus benefit of RDT. IBCR, incremental benefit:cost ratio; RDT, rapid diagnostic test.
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implementation in a model is complex. Some studies 
have addressed this aspect using process models or 
survival functions.30 31 We adopted a model incorpo-
rating seasonality using temperature- dependent param-
eters for mosquitoes11 and added delay terms for latency 
periods based on insights from another study9 to fit the 
incidence of malaria in South Korea. This new model 
better described the long latency period and seasonality 
of P. vivax malaria than those used in previous studies; 
its validity was demonstrated by accurately fitting weekly 
malaria incidence rates in South Korea.
The median time to report results using RDTs was 
1 hour (IQR 0–2 hours), whereas that for microscopy was 
13 hours (IQR 2–17 hours), with 13.3% of patients diag-
nosed with microscopy obtaining results after more than 
24 hours. As reducing the infectious period is crucial to 
prevent malaria transmission, reducing the diagnostic 
time by using RDTs is of great significance. The NHIIH 
is a general hospital with extensive experience in malaria 
treatment; considering that it is relatively early to suspect 
malaria and conduct tests for diagnosis, the effect of 
reducing the infectious period can be further maximised 
in areas where the incidence of P. vivax malaria is low. 
As the time interval from the symptom onset to P. vivax 
malaria diagnosis is a median of 9 days in non- risk areas 
of South Korea, the introduction of RDT helps improve 
patient prognosis.1 It also prevents the occurrence of 
unnecessary medical expenses and contributes to the 
prevention of new P. vivax malaria cases by reducing 
the infectious period. Furthermore, as shown from the 
sensitivity analysis, this also contributes to maximising the 
IBCR.
This study included two data sources (NHIIH and 
HIRA) for cost–benefit analysis. The average medical 
costs of a patient with P. vivax malaria diagnosed by 
microscopy alone and both microscopy and RDT were 
also compared. Data from the NHIIH guaranteed high 
reliability by directly calculating the actual medical 
expenses. The HIRA data had a disadvantage in that it 
was not possible to accurately specify the use of RDTs. 
Still, it had the merit of providing the average medical 
costs across the country because the HIRA reviews claims 
submitted by all healthcare providers. The results from 
this dataset showed trends similar to those of the results 
of the cost–benefit analysis using NHIIH data. Analysis 
using both data sources showed that the impact of RDTs 
on the cost–benefit and overall medical expenditures 
accumulated over time. In South Korea, all citizens are 
under the National Health Insurance Service funded 
by contributions, government subsidies and tobacco 
surcharges. The national government provides 14% of 
the total amount of funding, and the total expenditure 
on health insurance has increased annually.32 Since the 
increase in medical expenses is not just a problem in 
South Korea, efforts to reduce overall medical expenses 
are important, and we believe the results of our study can 
help in this regard.
This study has several strengths. First, we developed a 
dynamic compartmental mathematical model that could 
obtain results for more comprehensive impacts of RDT. 
Through this model, we could implement the transmis-
sion dynamics of P. vivax malaria so that we could estimate 
the impact of RDT introduction on overall future malaria 
incidences and national medical expenditures. Second, 
the malaria transmission model was designed through 
a set of values based on real data and fitting processes 
according to actual occurrences. The reduction in diag-
nostic time due to the use of RDTs obtained by analysing 
the actual hospital data also improved the reliability of 
the simulation. The cost–benefit analysis estimated the 
average cost per capita based on actual hospital data, and 
the reliability increased through the validation process 
using data from the entire country. Lastly, the sensitivity 
analysis demonstrated how the IBCR could change in 
various situations.
Despite the above strengths, this study has some limita-
tions. First, the dynamics of mosquito vectors for P. vivax 
malaria have been insufficiently studied. Thus, although 
we referred to foreign papers, these data are not neces-
sarily consistent with Korean mosquito dynamics even 
after correcting for the Korean environment. Second, 
relapse incidences were not accurately addressed, as 
described previously,31 since we mainly focused on the 
effects of RDTs. Third, this study did not consider future 
climate change scenarios since we estimated incidences 
for a relatively short period. Although the results were 
sensitive to mosquito dynamics that depend on climate 
changes, the influence of RDTs would be more critical 
in the global warming scenario. Fourth, we estimated 
the benefit indirectly from the summed medical cost 
data as we were unable to directly estimate the benefit 
from the data. Fifth, in HIRA data, the definitions of P. 
vivax malaria diagnosis by microscopy alone and both 
microscopy and RDT were made by researchers based 
on the time of RDT introduction. Still, it was difficult to 
completely classify the two test groups.
CONCLUSIONS
The introduction of RDTs can prevent new cases of P. 
vivax malaria by reducing the diagnostic time. RDTs also 
proved beneficial in the cost–benefit analysis and effects 
accumulated with increasing years. This not only meets 
the medical need to reduce the number of new cases 
but also contributes to the reduction of overall medical 
expenditures. Therefore, more active efforts are needed 
for the widespread adoption and use of RDTs.
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